Protective role of OPN-High macrophages in NASH

OPN-High 巨噬细胞在 NASH 中的保护作用

基本信息

  • 批准号:
    10752928
  • 负责人:
  • 金额:
    $ 53.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-05 至 2027-05-31
  • 项目状态:
    未结题

项目摘要

Non-alcoholic steatohepatitis (NASH) is emerging as a major worldwide cause of liver disease in children and adults. Recent studies demonstrate substantial heterogeneity in the phenotype of macrophages (MFs) infiltrating the liver during NASH. Recruited MFs exist as two subsets, with distinct activation states: (1) those closely resembling homeostatic Kupffer cells (KCs), or (2) lipid-associated MFs (LAMs). In 2020, a cluster of LAMs with high expression of osteopontin (OPN) was identified in livers with NASH. Notably, LAMs are differentially activated, compared to resident- and monocyte-derived KCs, and with a distinct ability to metabolize lipids. However, whether they also crosstalk with neighboring cells, to prevent steatosis and fibrosis in NASH, remains unknown. While recruitment of MFs into the liver, and subsequent activation, are considered proinflammatory and profibrotic events, currently a significant knowledge gap is a lack of understanding of whether OPNHigh MFs, are detrimental or protective in NASH. Preliminary data demonstrates that Spp1KI Mye are protected, whereas Spp1ΔMye have worse NASH activity scores than WT mice. Thus, our results suggest a paradigm shift, in that OPNHigh MFs may protect from NASH. Yet, the intercellular communication, and preventive and therapeutic potential of OPNHigh MFs, remain to be determined. Our overarching hypothesis is that OPNHigh MFs, by signaling to hepatocytes (HEPs) and hepatic stellate cells (HSCs), reduce liver steatosis and fibrosis, and protect from NASH. Aim 1 is to identify how OPNHigh MFs protect from steatosis. We hypothesize that OPNHigh MFs signal HEPs to upregulate arginase-2 (ARG2), which increases mitochondrial bioenergetics and fatty acid oxidation (FAO), reduces nitrosative stress, and protects from steatosis. To test this, first, we will identify the OPNHigh MF ‘secretome’ proteins that signal HEPs to upregulate ARG2; second, we will determine how the identified OPNHigh MF secretome proteins transactivate the ARG2 promoter, in HEPs; and third, we will elucidate how ARG2 increases mitochondrial bioenergetics and FAO, and reduces nitrosative stress, in HEPs. Aim 2 is to dissect how OPNHigh MFs protect from fibrosis. We hypothesize that OPNHigh MFs signal through secretome proteins to lower collagen-I, and/or modify the ‘matrisome’ landscape, to prevent fibrosis, and regulate cell behavior, in NASH. To prove this, first, we will identify the OPNHigh MF secretome proteins that signal HSCs to lower collagen-I deposition and/or increase its degradation; second, we will analyze whether OPNHigh MFs modify the matrisome landscape, and establish the OPNHigh MF-ECM correlation network; and third, we will perform liver scRNA-seq, and computationally identify how the OPNHigh MF-ECM network regulates cell behavior in NASH.
非酒精性脂肪性炎(NASH)是儿童和成人的主要肝脏疾病的主要肝脏疾病。 1)与脂质相关的MF(LAM)相似的那些类似于稳态的kupffer细胞(KC)。单核细胞衍生的KCS VER,是否与Neithboring细胞,Top Revent Steatosis和Nash中的Firosis的串扰尚不清楚nash活性比WT小鼠分数较差。星状细胞(HSC)1是为了确定opnhigh MF如何免受脂肪性的侵害,首先,我们将确定发出hepne arg2的opnhigh MF“分泌”蛋白;要从Fiteins到下部胶原蛋白和/或修改“ Matri”一些景观,以防止Firosis和调节细胞行为,以证明这一点。降低胶原蛋白沉积和/或增加的HSC是降解的;调节NASH中的细胞行为。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Natalia Nieto其他文献

Natalia Nieto的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Natalia Nieto', 18)}}的其他基金

22nd Liver Sinusoid Meeting
第22次肝正弦波会议
  • 批准号:
    10805816
  • 财政年份:
    2023
  • 资助金额:
    $ 53.38万
  • 项目类别:
Pathogenic role of a protein complex of liver origin as regulator of a proinflammatory program that drives hepatic and intestinal injury in alcoholic liver disease
肝脏来源的蛋白质复合物作为促炎程序的调节剂的致病作用,该程序驱动酒精性肝病中的肝脏和肠道损伤
  • 批准号:
    10663785
  • 财政年份:
    2021
  • 资助金额:
    $ 53.38万
  • 项目类别:
Pathogenic role of a protein complex of liver origin as regulator of a proinflammatory program that drives hepatic and intestinal injury in alcoholic liver disease
肝脏来源的蛋白质复合物作为促炎程序的调节剂的致病作用,该程序驱动酒精性肝病中的肝脏和肠道损伤
  • 批准号:
    10358521
  • 财政年份:
    2021
  • 资助金额:
    $ 53.38万
  • 项目类别:
High-mobility group box-1 and alcoholic liver disease
高迁移率族box-1与酒精性肝病
  • 批准号:
    10197739
  • 财政年份:
    2018
  • 资助金额:
    $ 53.38万
  • 项目类别:
High-mobility group box-1 and alcoholic liver disease
高迁移率族box-1与酒精性肝病
  • 批准号:
    10451824
  • 财政年份:
    2018
  • 资助金额:
    $ 53.38万
  • 项目类别:
Milk osteopontin, a nutritional therapeutic intervention for alcoholic hepatitis
牛奶骨桥蛋白,酒精性肝炎的营养治疗干预措施
  • 批准号:
    9088188
  • 财政年份:
    2015
  • 资助金额:
    $ 53.38万
  • 项目类别:
Milk osteopontin, a nutritional therapeutic intervention for alcoholic hepatitis
牛奶骨桥蛋白,酒精性肝炎的营养治疗干预措施
  • 批准号:
    9025179
  • 财政年份:
    2015
  • 资助金额:
    $ 53.38万
  • 项目类别:
Milk osteopontin, a nutritional therapeutic intervention for alcoholic hepatitis
牛奶骨桥蛋白,酒精性肝炎的营养治疗干预措施
  • 批准号:
    8428356
  • 财政年份:
    2012
  • 资助金额:
    $ 53.38万
  • 项目类别:
Milk osteopontin, a nutritional therapeutic intervention for alcoholic hepatitis
牛奶骨桥蛋白,酒精性肝炎的营养治疗干预措施
  • 批准号:
    8549929
  • 财政年份:
    2012
  • 资助金额:
    $ 53.38万
  • 项目类别:
Milk osteopontin, a nutritional therapeutic intervention for alcoholic hepatitis
牛奶骨桥蛋白,酒精性肝炎的营养治疗干预措施
  • 批准号:
    8693890
  • 财政年份:
    2012
  • 资助金额:
    $ 53.38万
  • 项目类别:

相似国自然基金

YTHDC1调控棕色脂肪组织大小、发育和能量代谢的作用机制研究
  • 批准号:
    32371198
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
糖尿病脂肪组织中SIRT3表达降低进而上调外泌体miR-146b-5p促进肾小管脂毒性的机制研究
  • 批准号:
    82370731
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
基于ADPN-Cer轴的柑橘黄酮调控能量负平衡奶牛脂肪组织脂解的分子机制
  • 批准号:
    32302767
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
ANGPTLs基因及其蛋白表达水平调控内脏脂肪组织影响健康衰老表型的前瞻性队列研究
  • 批准号:
    82373661
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
Acvrl1调控脂肪组织巨噬细胞M1/M2极化改善肥胖的机制研究
  • 批准号:
    82300973
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

The Renin-Angiotensin System in Air Pollution-Mediated Exacerbation of Obesity.
空气污染介导的肥胖加剧中的肾素-血管紧张素系统。
  • 批准号:
    10654124
  • 财政年份:
    2023
  • 资助金额:
    $ 53.38万
  • 项目类别:
Defining the role of mechanoresponsive adipocyte-to-fibroblast transition in wound fibrosis.
定义机械反应性脂肪细胞向成纤维细胞转变在伤口纤维化中的作用。
  • 批准号:
    10654464
  • 财政年份:
    2023
  • 资助金额:
    $ 53.38万
  • 项目类别:
Role of Interferon-Gamma / Interleukin-12 Axis in Metabolic Liver Disease
干扰素-γ/白介素-12 轴在代谢性肝病中的作用
  • 批准号:
    10735419
  • 财政年份:
    2023
  • 资助金额:
    $ 53.38万
  • 项目类别:
Role of SIK3 in PKA/mTORC1 regulation of adipose browning
SIK3 在 PKA/mTORC1 调节脂肪褐变中的作用
  • 批准号:
    10736962
  • 财政年份:
    2023
  • 资助金额:
    $ 53.38万
  • 项目类别:
The Influence of Developmental Exposure to Maternal Overnutrition and Metformin on Offspring Mitochondrial Health and Beta Cell Function
发育期暴露于母亲营养过剩和二甲双胍对后代线粒体健康和 β 细胞功能的影响
  • 批准号:
    10601500
  • 财政年份:
    2023
  • 资助金额:
    $ 53.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了